Skip to content
Head to head

Organon & Co vs Eli Lilly and Co

Side-by-side on the measures that matter, with a plain-English read. Full detail: OGN · LLY

Updated 8 minutes ago

1-year performance, rebased to 100

OGN +26.3%LLY +42.4%
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (79); Eli Lilly and Co has done best over the past year (+42%); Eli Lilly and Co earns the most per share.
OGNLLY
Snapshot
SectorDrug Manufacturers - GeneralDrug Manufacturers - General
Last price13.791,188.72
Change today+0.36%+2.70%
1-year return+31.2%+41.8%
Market cap$3.62B$1.12T
52-week range5.67 – 13.79778.93 – 1,292.65
Valuation
P/E (TTM)17.6839.90
P/E percentile, own 5-yr range99th6th
P/B3.6033.03
Dividend yield0.58%0.54%
Profitability & growth
EPS (TTM)0.7222.95
Net profit (TTM)$189.08M$21.60B
Revenue (TTM)$6.13B$79.67B
Revenue growth (YoY)-2.3%+47.7%
Gross margin52.7%83.4%
Operating margin19.0%49.7%
Net margin3.4%33.5%
Free cash flow (TTM)$434.00M$13.56B
Ownership & sentiment
Institutional ownership83.8%79.5%
Insider activity (12mo)34 buy / 16 sell37 buy / 13 sell
Short interest (% of float)6.7%0.8%
Analyst consensus--91% buy / 5% hold / 5% sell (22)
Analyst price target--$1,381 (+16%)
StockVane view
StockVane Quant RatingC (70)B (79)
Company
Employees10,00050,000
Founded20201876

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.